We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
+3.31%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$672M
AUM Growth
-$92.6M
Cap. Flow
-$92.4M
Cap. Flow %
-13.76%
Top 10 Hldgs %
83.41%
Holding
18
New
–
Increased
1
Reduced
5
Closed
–

Top Buys

Rank Stock Value
1
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$151K

Top Sells

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$40.9M
2
CEMP
Cempra, Inc.
CEMP
+$38.9M
3
CTLT
CATALENT, INC.
CTLT
+$11.8M
4
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$766K
5
ROKA
Sorrento Tech, Inc. Common Stock
ROKA
+$272K

Sector Composition

Rank Sector Weight
1 Healthcare 80.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
1
DELISTED
Esperion Therapeutics
ESPR
$134M 19.93%
1,637,125
-417,469
-20% -$40.9M
ZLTQ
2
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$76.7M 11.42%
2,602,738
+4,996
+0.2% +$151K
CEMP
3
DELISTED
Cempra, Inc.
CEMP
$75.4M 11.22%
2,193,060
-1,100,000
-33% -$38.9M
LOXO
4
DELISTED
Loxo Oncology, Inc
LOXO
$62.2M 9.27%
3,452,493
– –
CMRX
5
DELISTED
Chimerix, Inc.
CMRX
$47.3M 7.04%
1,022,943
– –
TTOO
6
DELISTED
T2 Biosystems, Inc
TTOO
$41M 6.1%
505
– –
ARAV
7
DELISTED
Aravive, Inc. Common Stock
ARAV
$34.7M 5.17%
379,928
– –
ADMA icon
8
ADMA Biologics
ADMA
$2.03B
$33.4M 4.98%
3,608,171
– –
SRNE
9
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$30M 4.47%
1,703,855
-59,645
-3% -$766K
AGRX
10
DELISTED
Agile Therapeutics
AGRX
$25.6M 3.82%
1,492
– –
ASXC
11
DELISTED
Asensus Surgical, Inc.
ASXC
$25M 3.72%
641,217
– –
CTLT
12
DELISTED
CATALENT, INC.
CTLT
$21M 3.13%
715,673
-391,056
-35% -$11.8M
DERM
13
DELISTED
Dermira, Inc.
DERM
$19.3M 2.88%
1,102,046
– –
PRTK
14
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$17.6M 2.62%
682,680
– –
PTX
15
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$11.9M 1.77%
201,000
– –
XENT
16
DELISTED
Intersect ENT, Inc
XENT
$10M 1.49%
350,000
– –
EVAR
17
DELISTED
Lombard Medical, Inc.
EVAR
$3.9M 0.58%
886,363
– –
ROKA
18
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$2.68M 0.4%
102,969
-9,273
-8% -$272K

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q2 2015 Portfolio in Review

As of Q2 2015, Aisling Capital held 18 positions worth $672M, down 12% from $764M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Aisling Capital withdrew a net $92.4M in Q2 2015, reducing 5 holdings. Its largest reduction was Esperion Therapeutics, cutting an estimated $40.9M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 84% a quarter earlier.

Against the trend, Aisling Capital added an estimated $151K to ZELTIQ Aesthetics, Inc..

  • Aisling Capital added most to ZELTIQ Aesthetics, Inc. in Q2 2015, an estimated $151K increase.
  • Aisling Capital's biggest Q2 2015 reduction was Esperion Therapeutics, cutting an estimated $40.9M.
  • Aisling Capital's ten largest holdings make up 83% of its $672M portfolio in Q2 2015.
  • Aisling Capital opened 0 new positions and closed 0 in Q2 2015.
  • Aisling Capital's portfolio value fell 12% quarter-over-quarter to $672M.

Based on Aisling Capital's 13F filing for Q2 2015, filed 14 Aug 2015.